Multicenter, double-blind, randomized, placebo-controlled phase I/II study to determine the
safety, tolerability, potential efficacy and dose finding of INP20, an oral immunotherapy in
peanut-allergic patients. The overall study design consists of two sequential periods of Part
A and Part B.
Part A is a dose escalation study in patients from 12 to 65 years old with a history of
immediate hypersensitive reaction to peanut protein. Six diferent oral-dose of INP20 will be
administered to 6 cohorts of patients once daily for 2 weeks.
Part B is a 6-month double-blind, placebo-controlled, randomized and parallel groups study.
Patients will be randomized in a 1:1:1 ratio into three (3) different treatment groups,
including placebo and the two doses of peanut protein selected from Part A. They will recieve
INP20 once daily for 6 months.